Do you offer durvalumab in combination with gemcitabine and cisplatin in patients with metastatic ampullary adenocarcinoma, given the fact that ABC-02 trial included patients with ampullary adenocarcinoma while TOPAZ trial excluded those patients?

Answer from: Medical Oncologist at Community Practice

Unfortunately we don't have robust contemporary data for ampullary adenocarcinoma. In general I would not apply the TOPAZ-1 study findings to this population.

Answer from: Medical Oncologist at Academic Institution

I do not.

Please select the option that best describes you:

Do you offer durvalumab in combination with gemcitabine and cisplatin in patients with metastatic ampullary adenocarcinoma, given the fact that ABC-02 trial included patients with ampullary adenocarcinoma while TOPAZ trial excluded those patients?

Related Questions